Prognostic factors in 401 elderly women with metastatic breast cancer

Oncology (Switzerland)

Volumn 86, Issue 3, 2014, Pages 143-151

  Follana, P ^a   Barriere J ^a   Chamorey, E ^a   Largillier, R ^b   Dadone, B ^a   Mari, V ^a   Hannoun Levi, J M ^a   Marcy, M ^a   Flipo, B ^a   Ferrero, J M ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b Centre Azuréen de Cancérologie Cancer Research Center   (France)

Author keywords

Metastatic breast cancer; Prognostics factors; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE; HORMONE RECEPTOR;

AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; PARTIAL MASTECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; BREAST METASTASIS; CANCER PATIENT; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CLINICAL PRACTICE; DISEASE SPECIFIC SURVIVAL; FOLLOW UP; METASTASIS FREE SURVIVAL; RETROSPECTIVE STUDY; SCARFF BLOOM RICHARDSON GRADE; SURVIVAL PREDICTION;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; MASTECTOMY, SEGMENTAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84895695357     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000357781     Document Type: Article

References (34)

1. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al: Cancer survival in five continents: A worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-756.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
3. Hospices Civils de Lyon, InVS, INCa, Francim, Inserm: Projections de l'incidence et de la mortalite par cancer en France pour l'annee 2011. Saint-Maurice, Institut de Vielle Sanitaire, 2011.
4. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al: SEER Cancer Statistics Review: 1975-2009 (Vintage 2009 Populations). Bethesda, National Cancer Institute, 2009.
5. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-Treatment trials. N Engl J Med 1999; 341: 2061-2067.
6. Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, et al: Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003; 21: 2268-2275.
7. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000; 92: 550-556.
8. Gazetas P, Estabrook A, O'Neil J, Sciacca R: Importance of adequate staging and of hormone receptors in women older than age 70 with breast cancer. Ann Surg 1992; 216: 22-26.
9. Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP: Breast cancer among the oldest old: Tumor characteristics, treatment choices, and survival. J Clin Oncol 2010; 28: 2038-2045.
10. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, et al: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003; 21: 3580-3587.
11. Yancik R, Wesley M, Ries L, Havlik R, Edwards B, Yates J: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-892.
12. Owusu C, Lash TL, Silliman RA: Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat 2007; 102: 227-236.
13. Mandelblatt JS, Hadley J, Kerner JF, et al: Patterns of breast carcinoma treatment in older women: Patient preference and clinical and physical influences. Cancer 2000; 89: 561-573.
14. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH: Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010; 21: 2169-2174.
15. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN: Is breast cancer survival improving? Cancer 2004; 100: 44-52.
16. Largillier R, Ferrero J-M, Doyen J, Barriere J, Namer M, Mari V, et al: Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008; 19: 2012-2019.
17. Freyer G, Braud AC, Chaibi P, Spielmann M, Martin JP, Vilela G, et al: Dealing with metastatic breast cancer in elderly women: Results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol 2006; 17: 211-216.
18. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
19. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer; a study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
20. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-Term follow-up. Histopathology 1991; 19: 403-410.
21. Milano G, Moll JL, Formento JL, Francoual M, Krebs BP, Namer M, et al: Simultaneous micro measurement of steroid receptors in breast cancer. Br J Cancer 1983; 48: 579-584.
22. Romain S, Formento JL, Guirou O, Francoual M, Milano G, Martin PM: Determination of oestrogen receptors by enzyme immunoassay: Technical differences between laboratories and their consequences. Eur J Cancer 1994; 30A:740-746.
23. Blankenstein MA: Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols: Experience of the E.O.R.T.C. Receptor Group. Breast Cancer Res Treat 1990; 17: 91-98.
24. Kaplan EL, Meier P: Non-parametric estimation form incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Cox DR: Regression models and life-Tables (with discussion). J Royal Stat Soc B 1972; 34: 138-220.
26. Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, et al: Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20: 1771-1785.
27. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J: Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: Analysis of 439 patients. Breast Cancer Res Treat 1999; 56: 67-78.
28. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, et al: Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998; 16: 2401-2408.
29. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al: Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 2004; 22: 3302-3308.
30. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM: Survival of patients with metastatic breast carcinoma. Cancer 2003; 97: 545-553.
31. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, et al: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983; 1: 776-786.
32. Ryberg M, Nielsen D, Osterlind K, Skovsgaard T, Dombernowsky P: Prognostic factors and long-Term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol 2001; 12: 81-87.
33. Patnaik JL, Byers T, DiGuiseppi C, Denberg TD, Dabelea D: The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011; 103: 1101-1111.
34. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al: Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13: E148-e160.